Karyopharm Therapeutics Inc (KPTI)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 17 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AIKaryopharm setzt generative KI-Werkzeuge fuer interne Produktivitaet ein (Entwuerfe, Stellenausschreibungen), erzielt damit aber keinen KI-Umsatz und trifft ausdruecklich keine autonomen KI-Entscheidungen in der klinischen Entwicklung.
View the full file — quotes, sources, reviewed filings
„We use and integrate artificial intelligence (“AI”) into our business processes, such as generative AI tools, primarily to support internal productivity activities, including drafting documents, job postings, and other non-clinical, non-operational materials."
Wir setzen kuenstliche Intelligenz („KI“) in unseren Geschaeftsprozessen ein und integrieren sie, etwa generative KI-Werkzeuge, vor allem zur Unterstuetzung interner Produktivitaet — darunter das Verfassen von Dokumenten, Stellenausschreibungen und anderen nicht-klinischen, nicht-operativen Materialien.
„We do not use our AI systems to make autonomous decisions related to clinical development, patient care, biometrics, pricing, credit, employment decisions, or other regulated or sensitive activities."
Wir nutzen unsere KI-Systeme nicht, um autonome Entscheidungen in Bezug auf klinische Entwicklung, Patientenversorgung, Biometrie, Preisgestaltung, Kreditvergabe, Beschaeftigungsfragen oder andere regulierte oder sensible Taetigkeiten zu treffen.
Filings Reviewed: 10-K 2026-02-13 · 10-Q 2026-05-14
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.36 | – | 31 | -9.50 | -100.80 | -26 | -26 |
| 2025: Q1 | -1.04 | – | 30 | -9.40 | -78.20 | -39 | -39 |
| 2025: Q2 | -1.64 | -256.60 | 38 | -11.40 | -98.20 | -19 | -19 |
| 2025: Q3 | -1.46 | – | 44 | 13.60 | -75.20 | -6 | -6 |
| 2025: Q4 | -4.51 | – | 34 | 11.60 | -299.90 | -12 | -12 |
| 2026: Q1 | -0.99 | – | 35 | 16.80 | -63.90 | -23 | -23 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Karyopharm Therapeutics Inc., ein Pharmaunternehmen in der Vermarktungsphase, entdeckt, entwickelt und vermarktet Medikamente, die gegen den nukleären Export gerichtet sind, zur Behandlung von Krebs und anderen Erkrankungen in den USA.
| Employees | 228 |
|---|---|
| Headquarters | Newton, MA |
| Website | karyopharm.com |
| IPO Date | 6. Nov 2013 |
| Next Earnings | 10. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Richard A. Paulson M.B.A. | President, CEO & Director | 1967 |
| Stuart Poulton | Executive VP & Chief Development Officer | 1973 |
| Reshma Rangwala M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Research | 1978 |
| Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1970 |
| Lori A. Macomber CPA | EVP, CFO & Treasurer | 1971 |
| Kristin Abate | VP, Chief Accounting Officer & Assistant Treasurer | – |
| Brendan Twohig Strong | Senior Vice President of Investor Relations | – |
| Michael J. Mano J.D. | Executive VP, Chief Legal Officer & Secretary | 1977 |
| James Accumanno J.D. | Chief Compliance Officer | – |
| Lisa DiPaolo | Executive VP & Chief Human Resource Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.